IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0262-2025

Syed Mustafa, Simon Houston

引用次数: 0

A 25-year-old pregnant woman with recurrent haemoptysis. 25岁孕妇，反复咯血。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0283-2025

Shan Kai Ing, Yih Hoong Lee, Ioanna Ting Yung Sim, Ming Chuen Ho, Nga Hung Ngu, Leh Ping Sii, Sherlyn Ing Lin Wong, Zakhirati Binti Zainol Abidin, Whilmore Anak Johin, Chan Sin Chai, Siew Teck Tie, Sze Shyang Kho

引用次数: 0

Enhancing tuberculosis care in lower and middle-income countries through digital adherence technologies. 通过数字坚持治疗技术加强低收入和中等收入国家的结核病治疗。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0173-2025

Rabbyia Ahmad, João Pedro Ramos, Raquel Duarte, Christoph Lange, Job Van Rest

{"title":"Enhancing tuberculosis care in lower and middle-income countries through digital adherence technologies.","authors":"Rabbyia Ahmad, João Pedro Ramos, Raquel Duarte, Christoph Lange, Job Van Rest","doi":"10.1183/20734735.0173-2025","DOIUrl":"10.1183/20734735.0173-2025","url":null,"abstract":"Tuberculosis (TB) remains a major public health challenge, particularly in low- and middle-income countries (LMICs), with treatment adherence being a critical issue. In recent years, digital adherence technologies (DATs) have emerged as a promising approach to enhance TB care and treatment adherence in these settings. Despite their potential to enhance treatment outcomes, their implementation faces challenges, including infrastructure demands, costs, and variability in effectiveness depending on the context. A critical aspect of DATs is their cost-effectiveness, which has shown mixed results across different LMICs. Some technologies, such as the medication sleeves/labels (e.g., 99DOTS), demonstrate low-cost alternatives to traditional directly observed therapy (DOT), while others report inconsistent outcomes. Throughout its implementation, DATs can be a source of intervention-generated inequality, where they may disproportionately benefit low-risk populations with better access to technology, potentially widening gaps in healthcare equity. However, when targeted effectively at high-risk groups, DATs can promote equitable health outcomes and enhance TB care delivery. The successful implementation of DATs requires context-specific strategies that address the unique challenges of LMICs, such as technology fatigue, data privacy, and the need for tailored interventions that consider socioeconomic and cultural factors. Leveraging the support of global health initiatives and collaborative funding mechanisms could help scale up DAT adoption and contribute to the global goal of TB elimination.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"22 1","pages":"250173"},"PeriodicalIF":4.5,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12910355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare cause of a solitary pulmonary mass. 罕见的孤立性肺肿块的病因。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0313-2025

Syahrinnaquiah Samsuddin, Yen Shen Wong, Aisya Natasya Musa, Am Basheeri Alias, Roqiah Fatmawati Abdul Kadir, Nor Salmah Bakar

引用次数: 0

An uncommon cancer mimic diagnosed via endobronchial ultrasound. 通过支气管内超声诊断的罕见癌症。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0185-2025

Louise Byrne, David Quigley, Finbarr O'Connell, Parthiban Nadarajan

引用次数: 0

My approach to respiratory sepsis: pulmonary. 我治疗呼吸道败血症的方法是肺部。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0034-2025

Chin Yang Song, Saoirse Flanagan, Michael Harrison

引用次数: 0

Pleural effusion in haematological malignancies: an educational position statement. 恶性血液病中的胸腔积液：教育立场声明。

IF 4.5

Breathe Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0265-2025

Olivia Walsh, Arran Patel, Najib Rahman, Graham Collins

{"title":"Pleural effusion in haematological malignancies: an educational position statement.","authors":"Olivia Walsh, Arran Patel, Najib Rahman, Graham Collins","doi":"10.1183/20734735.0265-2025","DOIUrl":"10.1183/20734735.0265-2025","url":null,"abstract":"Pleural effusion is a known complication of haematological malignancies, including lymphomas, leukaemias and multiple myeloma. The true overall incidence of pleural effusion in haematologic disorders is not precisely established, but case series suggest it occurs in roughly 20-48% of patients with these diseases. Among all malignant pleural effusions (MPEs), about 10-16% are attributable to haematologic cancers (especially lymphomas/leukaemias). The development of a pleural effusion in this context poses significant diagnostic challenges, as traditional tests such as pleural fluid cytology or pleural biopsy often have low diagnostic yield. Importantly, the underlying mechanisms of pleural effusion in haematological malignancy are diverse, ranging from direct pleural infiltration and mediastinal nodal obstruction to chylothorax, cardiac dysfunction, and treatment-related complications. These varied aetiologies not only complicate diagnosis but also have direct implications for both immediate and long-term management. Moreover, emerging evidence indicates that the presence of a pleural effusion in patients with haematological malignancies may reflect advanced disease or evolving complications and is often associated with a poorer prognosis. This position statement provides an overview of the prevalence, pathophysiology, diagnostic approach, management strategies, and prognosis of pleural effusions in haematological malignancies, and offers evidence-based recommendations to guide clinical practice.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"22 1","pages":"250265"},"PeriodicalIF":4.5,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12910353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of adverse events in TB care and active TB drug safety monitoring. 结核治疗中不良事件的管理和主动结核药物安全监测。

IF 3.4

Breathe Pub Date : 2026-01-27 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0203-2025

Shamsuddeen Yusuf Ma'aruf, Aparna Sharma, Shannon Fox, Raquel Duarte, Christoph Lange, Simon Tiberi

{"title":"Management of adverse events in TB care and active TB drug safety monitoring.","authors":"Shamsuddeen Yusuf Ma'aruf, Aparna Sharma, Shannon Fox, Raquel Duarte, Christoph Lange, Simon Tiberi","doi":"10.1183/20734735.0203-2025","DOIUrl":"https://doi.org/10.1183/20734735.0203-2025","url":null,"abstract":"Tuberculosis (TB) remains the leading cause of death from a single infectious agent, with 10.8 million cases reported in 2023. While treatment is generally effective, both drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) regimens are associated with adverse events (AEs) that compromise adherence and outcomes. In this viewpoint, we highlight the most clinically relevant AEs: hepatotoxicity, cutaneous reactions and ocular toxicity in DS-TB; and linezolid-associated neuropathy, myelosuppression, QT prolongation and hepatotoxicity in DR-TB. We argue that structured safety monitoring and integration of active TB Drug Safety Monitoring and Management into routine care are critical to improving patient safety. Looking ahead, pharmacogenomics, therapeutic drug monitoring, predictive algorithms and digital health solutions offer opportunities to move from reactive to proactive AE management. By prioritising monitoring, innovation and patient-centred approaches, TB programmes can reduce the burden of AEs, improve adherence and achieve better outcomes.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"22 1","pages":"250203"},"PeriodicalIF":3.4,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12839461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rehabilitation for individuals with post-tuberculosis lung disease. 结核病后肺病患者的康复。

IF 3.4

Breathe Pub Date : 2026-01-27 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0056-2025

Ohanna Kirakosyan, Haike Verbree, Marieke M van der Zalm, Rebecca Nightingale, Marcela Muñoz-Torrico, Denise Rossato Silva, Sally J Singh, Rosella Centis, Raquel Duarte, Onno W Akkerman, Giovanni Battista Migliori

{"title":"Rehabilitation for individuals with post-tuberculosis lung disease.","authors":"Ohanna Kirakosyan, Haike Verbree, Marieke M van der Zalm, Rebecca Nightingale, Marcela Muñoz-Torrico, Denise Rossato Silva, Sally J Singh, Rosella Centis, Raquel Duarte, Onno W Akkerman, Giovanni Battista Migliori","doi":"10.1183/20734735.0056-2025","DOIUrl":"https://doi.org/10.1183/20734735.0056-2025","url":null,"abstract":"Tuberculosis (TB) continues to be a global clinical and public health threat, particularly in low- and middle-income countries. TB care has primarily been centred around timely diagnosis and expanding access to treatment. Post-TB lung disease (PTLD), characterised by persistent respiratory symptoms, functional impairment and structural lung changes, is highly prevalent among TB survivors, with a prevalence ranging from 40% to 90%. This requires an effort to evaluate TB survivors in need of further care at the end of anti-TB treatment, for consideration of pulmonary rehabilitation. This review provides an overview of the current evidence and best practices in pulmonary rehabilitation for PTLD. This article aims to bridge the gap between evidence and practice, supporting tailored, multidisciplinary approaches to pulmonary rehabilitation, building on the existing experiences and challenges from diverse settings. Furthermore, this review supports the ongoing educational efforts of healthcare professionals to reframe TB care, placing long-term health and patient wellbeing at the centre of post-TB management.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"22 1","pages":"250056"},"PeriodicalIF":3.4,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12839462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary infections. 肺部感染。

IF 4.5

Breathe Pub Date : 2026-01-27 eCollection Date: 2026-01-01 DOI: 10.1183/20734735.0363-2025

Imran Sulaiman

引用次数: 0

Breathe最新文献